Concepedia

FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.

Khalil Ullah Hashmi, Badshah Khan, Parvez Ahmed, Shahid Raza, Iftikhar Hussaın, Ahsan Mahmood, Hamid Iqbal, Hamid Saeed Malik, Masood Anwar

PubMed · 2005 · 10 citations · 24 references

Abstract

In our experience, FLAG-IDA is well tolerated and effective regimen in relapsed/refractory acute leukaemias. The toxicity is acceptable, enabling most patients to receive further treatment, including transplantation procedures.

References

24

Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study

Catherine P. Leith, Kenneth J. Kopecky, John E. Godwin et al. · Blood · 1997 · 868 citations

Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.

Varsha Gandhi, Elihu H. Estey, M Keating et al. · Journal of Clinical Oncology · 1993 · 334 citations

Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.

Elihu H. Estey, Peter F. Thall, Michael Andreeff et al. · Journal of Clinical Oncology · 1994 · 296 citations

Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy

J. C. Biggs, MM Horowitz, Gale Rp et al. · Blood · 1992 · 217 citations · Full text

Randomized Phase II Study of Fludarabine + Cytosine Arabinoside + Idarubicin ± All-Trans Retinoic Acid ± Granulocyte Colony-Stimulating Factor in Poor Prognosis Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Syndrome

Elihu H. Estey, Peter F. Thall, Sherry Pierce et al. · Blood · 1999 · 203 citations